Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Clinical trial NCT05315700 · RECRUITING
Trial details
- NCT number
- NCT05315700
- Sponsor
- ORIC Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-10
- Primary completion
- 2026-09-01
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.